Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 112 • 2016 ACR/ARHP Annual Meeting
Leveraging a Learning Network to Implement and Standardize Self-Management Support into Care Delivery: Experience of Pediatric Rheumatology Care and Outcomes Improvement Network
Janalee Taylor¹, Avani Modi², Kristin Loiselle², Julie Gomez³, Karla B. Jones⁴, Sheetal S. Vora⁵, Julia Harris⁶, Beth Gottlieb⁷, Lisa Robbins⁸, Tzielan Lee⁹, Kristi Whitney-Mahoney¹⁰, Murray Passo¹¹, Melanie Kohlheim¹², Laura Curtis¹², Anjie Vago¹³, Kerry Ferraro¹², Kate Trevey¹², Jennifer Gil¹², Laura Bouslaugh¹², Angela Young¹², Nancy Griffin¹⁴, Anne Paul¹⁵, Carole M. Lannon¹⁴ and Esi Morgan¹⁶, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Center for Treatment Adherence and Self-Management, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Rheumatology, Nationwide Children's, Columbus, OH, ⁵Pediatric Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ⁶Children's Mercy Kansas City, Kansas City, MO, ⁷Pediatrics, Cohen Children's Medical Center, Lake Success, NY, ⁸Penn State Hershey Children's Hospital, Hershey, PA, ⁹Pediatric Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ¹⁰The Hospital for Sick Children, Toronto, ON, Canada, ¹¹Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, ¹²Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, OH, ¹³Pediatric Rheumatology Care and Outcomes Improvement Network, cincinnati, OH, ¹⁴James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁵Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁶Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Disease outcomes can depend, to a large extent, on one’s ability to manage their condition effectively. For children with JIA this means managing oral,…
Abstract Number: 948 • 2016 ACR/ARHP Annual Meeting
Subcutaneous Abatacept in Patients with Polyarticular-Course Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Efficacy and Safety
DJ Lovell¹, N Ruperto², N Tzaribachev³, G Vega-Cornejo⁴, I Louw⁵, A Berman^6,7, I Calvo⁸, R Cuttica⁹, G Horneff¹⁰, F Avila-Zapata¹¹, J Anton¹², R Cimaz¹³, E Solau-Gervais¹⁴, R Joos¹⁵, G Espada¹⁶, X Li¹⁷, M Nys¹⁸, R Wong¹⁷, S Banerjee¹⁷, Hermine I. Brunner¹⁹, A Martini²⁰ and For Pediatric Rheumatology International Trials Organization (PRINTO)/Pediatric Rheumatology Collaborative Study Group (PRCSG), ¹Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Istituto G. Gaslini Pediatria II Reumatologia, Genoa, Italy, ³Pediatric Rheumatology, Bad Bramstedt, Germany, ⁴Clinica de Rheumatología y Enfermedades Autoinmunes (CREA), Hospital México Americano, Guadalajara Jalisco, Mexico, ⁵Panorama Medical Centre, Cape Town, South Africa, ⁶Universidad Nacional de Tucuman and Centro Médico Privado de Reumatología, Tucumán, Argentina, ⁷Universidad Nacional de Tucuman and Centro Médico Privado de Reumatología, Tucuman, Argentina, ⁸Hospital Univ. La Fe, Valencia, Spain, ⁹Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, ¹⁰Centre Paediatric Rheumatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ¹¹Star Medica Hospital, Merida, Mexico, ¹²Unitat de Reumatologia Pediàtrica, Hospital Sant Joan de Déu, Barcelona, Spain, ¹³Pediatrics, Ospedale Pediatrico Anna Meyer, Florence, Italy, ¹⁴Hôpital de la Miletrie, Poitiers, France, ¹⁵University Hospital Gent, Gent, Belgium, ¹⁶Cramer 1853 4°C, Hospital de Ninos Dr Ricardo Gutierrez, Buenos Aires, Argentina, ¹⁷Bristol-Myers Squibb, Princeton, NJ, ¹⁸Bristol-Myers Squibb, Braine-l’Alleud, Belgium, ¹⁹Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²⁰Istituto G. Gaslini Pediatria II Reumatologia and University of Genova, Genoa, Italy
Background/Purpose: IV abatacept (ABA) 10 mg/kg every 4 weeks was well tolerated and effective in reducing the signs and symptoms of polyarticular-course juvenile idiopathic arthritis…
Abstract Number: 335 • 2016 ACR/ARHP Annual Meeting
High Risk of Osteoporosis and Long Term Joint Damage in Adults with a History of Juvenile Idiopathic Arthritis
Hiranda Dodanwala¹, Danielle Feger¹, Nicholas Longson², Nancy J. Olsen³, Barbara E. Ostrov^4,5 and Rayford R. June⁶, ¹Medicine - Division of Rheumatology, Penn State Milton S. Hershey Medical Center, Hershey, PA, ²Johns Hopkins University, Baltimore, MD, ³Divsion of Rheumatology, Department of Medicine, Penn State MS Hershey Medical Center, Hershey, PA, ⁴Pediatrics, Penn State Hershey Medical Center, Hershey, PA, ⁵Pediatrics, Penn State Hershey Children's Hospital, Hershey, PA, ⁶Rheumatology, Penn State Hershey Medical Center, Hershey, PA
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a heterogeneous group of chronic inflammatory arthritides. JIA is the most common cause of musculoskeletal disability in children, and…
Abstract Number: 949 • 2016 ACR/ARHP Annual Meeting
Comparison of Treatment Response, Remission Rate and Drug Adherence in Polyarticular Juvenile Idiopathic Arthritis Patients Treated with Etanercept, Adalimumab or Tocilizumab
Gerd Horneff^1,2, Ariane Klein³, Kirsten Minden^4,5, Hans-Iko Huppertz⁶, Frank Weller-Heinemann⁷, Jasmin B. Kuemmerle-Deschner⁸, Johannes Peter Haas⁹ and Toni Hospach¹⁰, ¹Asklepios Klinik Zentrum für Allgemeine Paediatrie und Neonatologie, Sankt Augustin, Germany, ²Department of Pediatrics, Centre of Pediatric Rheumatology, Sankt Augustin, Germany, ³Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁴Epidemiology, Charite, DRFZ, Berlin, Germany, ⁵Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany, ⁶Klinikum Bremen-Mitte, Prof.-Hess-Kinderklinik, Bremen, Germany, ⁷Prof.-Hess-Kinderklinik, Bremen,, Berlin, Germany, ⁸Universitätsklinikum Tübingen, Klinik fuer Kinder- und Jugendmedizin, Tübingen, Germany, ⁹German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, ¹⁰Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgard, Germany
Background/Purpose: Treatment response, remission rates and compliance in polyarticular JIA patients treated with adalimumab(ADA), etanercept(ETA), or tocilizumab(TCZ) were analyzed in clinical practice. Methods: Data from the German BIKER…
Abstract Number: 376 • 2016 ACR/ARHP Annual Meeting
Initial Validation of the Patient Reported Outcomes Measurement Information System Pediatric Pain Intensity Scale in Juvenile Idiopathic Arthritis, Juvenile Fibromyalgia and Sickle Cell Disease
Esi Morgan¹, Constance Mara², Bin Huang³, Adam Carle⁴, Kenneth Goldschneider⁵, Carlton Dampier⁶ and Susmita Kashikar-Zuck⁷, ¹Pediatric Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH, ²James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Anesthesia, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Department of Pediatrics (Hematology-Oncology), Emory University School of Medicine, Atlanta, GA, ⁷Behavioral Medicine & Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: The Patient Reported Outcomes Measurement Information System(PROMIS) is a publicly available assessment system offering multiple measures to assess physical, mental and social health.…
Abstract Number: 1240 • 2016 ACR/ARHP Annual Meeting
A Minority of Patients Utilize Most of Healthcare Resources in Rheumatoid Arthritis, Psoriatic Arthritis, Juvenile Idiopathic Arthritis, and Axial Spondyloarthritis
Nina Mars¹, Anne M Kerola², Markku J Kauppi^3,4, Outi Elonheimo^5,6, Santeri Huvinen^5,6 and Tuulikki Sokka-Isler^7,8, ¹University of Helsinki, Helsinki, Finland, ²Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, ³School of Medicine, University of Tampere, Tampere, Finland, ⁴Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ⁵Network of Academic Health Centres, Department of Medicine, University of Helsinki, Helsinki, Finland, ⁶FCG Finnish Consulting Group Ltd., Helsinki, Finland, ⁷Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ⁸RAID working group for EULAR, Zurich, Switzerland
Background/Purpose: Rheumatoid arthritis (RA) is associated with high healthcare costs, but little is known about how the costs compare to other chronic rheumatic diseases. We…
Abstract Number: 2026 • 2015 ACR/ARHP Annual Meeting
A Novel Technique for Quantifying Synovial Enhancement of Temporomandibular Joints from Mris of Patients with Juvenile Idiopathic Arthritis
Cory M. Resnick¹, Pouya Vakilian², Micheal Breen³, David Zurakowski⁴, Zachary S. Peacock⁵ and Leonard B. Kaban⁵, ¹Plastics and Oral Surgery, Boston Children's Hospital, boston, MA, ²Harvard School of Dental Medicine, Boston, MA, ³Radiology, Boston Children's Hospital, Boston, MA, ⁴Departments of Anesthesia and Surgery, Boston Children’s Hospital, Boston, MA, ⁵Oral and Maxillofacial Surgery, Massachusetts General Hospital, Boston, MA
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) commonly affects the temporomandibular joints (TMJ) and may cause growth disturbance, functional limitation and facial deformity. Early diagnosis and management…
Abstract Number: 2171 • 2015 ACR/ARHP Annual Meeting
A Comparison of Maternal Outcomes in Women with and without Juvenile Idiopathic Arthritis
Debbie Ehrmann Feldman¹, Sasha Bernatsky², Evelyne Vinet³, Ciarán M. Duffy⁴, Elizabeth Hazel⁵, Garbis Meshefedjian⁶, Marie-Pierre Sylvestre⁷ and Anick Bérard¹, ¹Université de Montréal, Montréal, QC, Canada, ²Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada, ³McGill University Health Centre, Montreal, QC, Canada, ⁴Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ⁵Rhematology, McGill University Health Centre, Montreal, QC, Canada, ⁶Public Health Department of Montreal, Montreal, QC, Canada, ⁷Université de Montréal, Montreal, QC, Canada
Background/Purpose: Although there is a higher frequency of adverse maternal outcomes in mother with rheumatoid arthritis, little is known regarding mothers with juvenile idiopathic arthritis…
Abstract Number: 2416 • 2015 ACR/ARHP Annual Meeting
Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Pediatric Patients from Six to Less Than Eighteen Years of Age with Juvenile Idiopathic Arthritis
Hermine I. Brunner¹, Nicolino Ruperto², Nikolay Tzaribachev³, Zbigniew Zuber⁴, Elena Koskova⁵, Ivan Foeldvari⁶, Eizbieta Smolewska⁷, Gerd Horneff⁸, Charles Mebus⁹, Umberto Conte¹⁰, Rong Wang⁹, Christine Alvey⁹, Manisha Lamba⁹, Anasuya Hazra¹¹, Daniel Lovell¹² and Alberto Martini¹³, ¹Pediatric Rheumatology Collaborative Study Group, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Istituto G. Gaslini, Pediatria II, PRINTO, Genoa, Italy, ³Pediatric Rheumatology, Bad Bramstedt, Germany, ⁴St Louis Children’s Hospital ODS Rheumatology and Neurology, Krakow, Poland, ⁵Institute of Rheumatic Diseases, Piestany, Slovakia, ⁶Hamburger Zentrum für Kinder-und Jugendrheumatologie, Hamburg, Germany, ⁷Department of Pediatric Cardiology and Rheumatology, Medical University of Lodz, Lodz, Poland, ⁸Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ⁹Pfizer Inc, Groton, CT, ¹⁰Pfizer Inc, New York, NY, ¹¹Pfizer Inc, Collegeville, PA, ¹²Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹³Istituto G. Gaslini, Pediatria II, PRINTO, and University of Genoa, Genoa, Italy
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of adult patients with rheumatoid arthritis (RA). We report the pharmacokinetics (PK), safety and…
Abstract Number: 2423 • 2015 ACR/ARHP Annual Meeting
An Open-Label Extension Study to Assess the Long-Term Safety and Clinical Benefit of Etanercept on Children and Adolescents with Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, or Psoriatic Arthritis: A 4-Year Update
Nicolino Ruperto¹, Tamas Constantin², Ivan Foeldvari³, Jelena Vojinovic⁴, Gerd Horneff⁵, Rubén Burgos-Vargas⁶, Irina Nikishina⁷, Jonathan Akikusa⁸, Tadej Avcin⁹, Jeffrey Chaitow¹⁰, Elena Koskova¹¹, Bernard R. Lauwerys¹², Inmaculada Calvo-Penedes¹³, Berit Flato¹⁴, Maria Luz Gamir Gamir¹⁵, Hans-Iko Huppertz¹⁶, Juan Jose Jaller Raad¹⁷, Katerina Jarosova¹⁸, Jordi Anton¹⁹, Marie Macku²⁰, William Jose Otero Escalante²¹, Lidia Rutkowska-Sak²², Ralf Trauzeddel²³, Carine Wouters²⁴, Ronald Pedersen²⁵, Sameer Kotak²⁶, Jack F Bukowski²⁷, Tina Hinnershitz²⁸, Bonnie Vlahos²⁹ and Alberto Martini³⁰, ¹Pediatria II, PRINTO, Istituto G. Gaslini, Universita' di Genova, Genova, Italy, ²Semmelweis University, Budapest, Hungary, ³Hamburg Centre for Child and Adolescent Rheumatology, Hamburg, Germany, ⁴Faculty of Medicine, University of Nis, Nis, Serbia, ⁵Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁶Rheumatology, Hospital General de Mexico, Mexico city, Mexico, ⁷V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁸Rheumatology, Royal Children's Hospital, Melbourne, Australia, ⁹Allergology, Rheumatology and Clinical Immunology, University Medical Center Ljubljana, Ljubljana, Slovenia, ¹⁰The Sydney Children's Hospital Network, Sydney, Australia, ¹¹National Institute of Rheumatic Diseases, Piestany, Slovakia, ¹²Cliniques Universitaires Saint-Luc, Brussels, Belgium, ¹³Hospital Universitario y Piltecnico La Fe, Valencia, Spain, ¹⁴Oslo University Hospital, Oslo, Norway, ¹⁵Rheumatology, Hospital Ramon y Cajal Unidad de Reumatologia Pediatrica, Madrid, Spain, ¹⁶Klinikum Bremen-Mitte, Prof.-Hess-Kinderklinik, Bremen, Germany, ¹⁷Centro de Reumatologia y Ortopedia, Barranquilla, Colombia, ¹⁸Revmatologicky ustav, Prague, Czech Republic, ¹⁹Unitat de Reumatologia Pediàtrica, Hospital Sant Joan de Déu, Barcelona, Spain, ²⁰1, Facutly Children's Hospital Brno, Brno, Czech Republic, ²¹Servimed S.A.S, Santander, Colombia, ²²Instytut Reumatologii, Klinika i Poliklinika Reumatologii Wieku Rozwojowego, Warszawa, Poland, ²³HELIOS Klinikum Berlin-Buch Klinik fuer Kinder- und Jugendmedizin, Berlin, Germany, ²⁴UZ Leuven, Leuven, Belgium, ²⁵Department of Biostatistics, Pfizer, Collegeville, PA, ²⁶Global Health and Value, Pfizer, New York, NY, ²⁷Pfizer, Collegeville, PA, ²⁸Specialty Care MDG, Pfizer, Collegeville, PA, ²⁹GIPB - Clinical Sciences, Pfizer, Collegeville, PA, ³⁰Istituto G. Gaslini, Universita' di Genova, Genova, Italy
Background/Purpose: A Phase 3b, open-label, multicenter study (CLIPPER; NCT00962741) demonstrated the efficacy of etanercept (ETN) in subjects with the extended oligoarticular (eo), enthesitis-related (ERA), and…
Abstract Number: 2432 • 2015 ACR/ARHP Annual Meeting
The Preventive Effect of Methotrexate on Uveitis Onset in JIA Depends on Uveitis Risk Factors
Mikhail Kostik¹, Ekaterina Gaidar¹, Margarita Dubko¹, Ludmila Snegireva², Vera Masalova², Irina Chikova¹, Eugenia Isupova³, Tatiana Nikitina⁴, Elena Serogodskaya¹, Olga Kalashnikova¹, Angelo Ravelli⁵ and Vyacheslav Chasnyk³, ¹State Pediatric Medical University, Saint-Petersburg, Russia, ²Hospital Pediatrics, State Pediatric Medical University, Saint-Petersburg, Russia, ³Hospital Pediatry, State Pediatric Medical University, Saint-Petersburg, Russia, ⁴State Pediatric Medical University, St. Petersburg, Russia, ⁵Pediatria-II, IRCCS G. Gaslini and University of Genova, Genova, Italy
Background/Purpose: Uveitis is the most common extra-articular manifestation of juvenile idiopathic arthritis (JIA), often entirely asymptomatic but could be sight-threatening. The main predictors of uveitis…
Abstract Number: 2437 • 2015 ACR/ARHP Annual Meeting
Experience with Tocilizumab for Treatment of 56 Children with Systemic Juvenile Idiopathic Arthritis in the German JIA Biologics Register
Gerd Horneff¹, Gerd Ganser², Johannes Peter Haas³, Toni Hospach⁴, Ralf Trauzeddel⁵, Hans-Iko Huppertz⁶, J B. Kuemmerle-Deschner⁷, Kirsten Minden⁸ and BIKER Registry Study Group, ¹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ²Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, ³German Centre for Rheumatology in Children and Young People, Garmisch-Partenkirchen, Germany, ⁴Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgard, Germany, ⁵HELIOS Klinikum Berlin-Buch Klinik fuer Kinder- und Jugendmedizin, Berlin, Germany, ⁶PRINTO, IRCCS G. Gaslini, Genoa, Italy, ⁷Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, ⁸DRFG, Berlin, Germany
Background/Purpose: Tocilizumab (TOC) has become a valuable option for treatment of systemic juvenile idiopathic arthritis (sJIA), which significantly improved the outcome of patients. The aim…
Abstract Number: 930 • 2015 ACR/ARHP Annual Meeting
Evaluation of Temporomandibular Joint Arthritis with Ultrasound in Juvenile Idiopathic Arthritis
Edward J. Oberle^1,2, James Nocton³ and Arthur Meyers⁴, ¹Pediatrics, Ohio State University, Columbus, OH, ²Pediatric Rheumatology, Nationwide Children's Hospital, Columbus, OH, ³Pediatrics, Medical College of Wisconsin, Milwaukee, WI, ⁴Radiology, Children's Hospital of Wisconsin, Milwaukee, WI
Background/Purpose: Temporomandibular joint (TMJ) arthritis is a common yet widely under recognized feature of Juvenile Idiopathic Arthritis (JIA). It is often clinically silent and difficult…
Abstract Number: 2444 • 2015 ACR/ARHP Annual Meeting
Accelerometer-Assessed Daily Physical Activity in Relation to Pain Cognitions and Quality of Life in Juvenile Idiopathic Arthritis
Mette Noergaard¹, Johanne Lomholt², Mikael Thastum², Morten Herlin³, Marinka Twilt⁴ and Troels Herlin⁴, ¹Department of Physiotherapy, Aarhus University Hospital, Aarhus, Denmark, ²Psychology and Social Sciences, Aarhus University, Aarhus, Denmark, ³Pediatrics, Aarhus University Hospital, Aarhus, Denmark, ⁴Pediatric Rheumatology Clinic, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) has been associated with decreased physical activity (PA). However, accurate, objective measurements of PA related to potential factors limiting PA…
Abstract Number: 957 • 2015 ACR/ARHP Annual Meeting
Double Blind Placebo Controlled Randomized Trial of Probiotics in Enthesitis-Related-Arthritis Category of JIA: Effect on Clinical and Immunological Parameters
Anuj Shukla¹, Priyanka Gaur² and Amita Aggarwal¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Gut microflora influences the development and homeostasis of the immune system. Dysbiosis has been reported in various immuno-inflammatory diseases. Pathogenesis of enthesitis-related-arthritis (ERA) category…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].